(Isstories Editorial):- Boston, Massachusetts Feb 12, 2026 (Issuewire.com) – Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that Chris Adams, Founder and CEO, will be a featured speaker at the upcoming Outsourcing in Clinical Trials (OCT) West Coast conference. The event will take place in Burlingame, California, from February 11-12, 2026.
The OCT West Coast conference is a premier industry gathering focused on the operational challenges and innovative solutions within clinical development. This year’s program emphasizes the integration of advanced imaging and AI in clinical trials, a core component of the Andarix precision medicine platform.
Mr. Adams will deliver a presentation titled “Optimizing Clinical Operations for Targeted Radiopharmaceuticals”. His session will discuss strategies for navigating the unique logistical and regulatory complexities of radiopharmaceutical trials, including the coordination of companion diagnostics and the supply chain for short-lived therapeutic isotopes.
More on Isstories:
- Navigating the Radiopharmaceutical Frontier: Strategic Outsourcing for Targeted Oncology Trials
- Solaire Resort Entertainment City and Solaire Resort North Honored by Forbes Travel Guide’s 2026 Star Award
- The International MLS [IMLS]® Launches It’s International New Home Developments Automated Platform
- Mansa AI Charts a Path Toward Fully Agent-Driven Decentralized Workflows
- Buffalo Biodiesel Acquires Transfer Station in Ulster County as Part of Strategic Expansion Across Eastern U.S.
“The OCT West Coast conference provides an essential forum for clinical leaders to address the hurdles of modern oncology research,” said Chris Adams, CEO of Andarix Pharmaceuticals. “I look forward to discussing how precision targeting and integrated imaging can not only improve patient selection but also streamline the execution of complex clinical trials for underserved cancer populations.”
Andarix continues to gain momentum with its proprietary peptide-targeted radionuclide technology, which leverages somatostatin analogs to deliver diagnostic and therapeutic radioisotopes directly to solid tumors, specifically targeting lung, pancreatic, and neuroendocrine cancers.
For more information about the OCT West Coast conference or to register, please visit the official conference website.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized cancer therapy, developing next-generation targeted radiotherapeutics for oncology. The company’s proprietary platform utilizes somatostatin peptide conjugates to enable a “theranostic” approach–identifying patients through diagnostic imaging and delivering high-energy radiotherapy directly to tumor cells while sparing healthy tissue. Headquartered in Somerville, MA, Andarix is dedicated to improving outcomes for patients with hard-to-treat and rare cancers.
Media Contact: Andarix Pharmaceuticals 617-957-9858 [email protected]
